Want to see JP:4890 full AI Analyst Report?
4890 Stock Chart & Stats
¥340.00
¥1.00(0.24%)
At close: 4:00 PM EST
¥340.00
¥1.00(0.24%)
Day’s Range― - ―
52-Week Range¥210.00 - ¥478.00
Previous CloseN/A
Volume43.10K
Average Volume (3M)31.02K
Market Cap
¥7.19B
Enterprise Value¥5.27K
Total Cash (Recent Filing)¥969.85M
Total Debt (Recent Filing)¥69.21M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-29.59
Shares Outstanding25,969,738
10 Day Avg. Volume26,720
30 Day Avg. Volume31,016
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.77
Price to Sales (P/S)37.86
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And Potential Earnings InflectionFirst-quarter revenue recovery and management’s FY2027 growth and profit targets indicate demand may be rebuilding after the prior collapse. If execution continues, greater scale could restore operating leverage and reduce funding pressure, although the forecast remains unproven.
Conservative Balance SheetLow leverage and a substantial equity base provide resilience while the business remains volatile. This structure limits interest burdens and preserves access to strategic investment or additional financing if management can convert the recent revenue recovery into sustainable profitability.
Strong Gross Margin PotentialA gross margin near 66% suggests the company’s products can retain meaningful value after direct costs. With sufficient revenue scale, this underlying product economics could support operating leverage and improve profitability, although the current fixed-cost base remains too large.
Bears Say
Severe Revenue And Profitability DeteriorationThe sharp revenue contraction and deep loss demonstrate major earnings instability, weakening visibility into the commercial model. Even with a strong gross margin, insufficient volume leaves fixed costs uncovered and could delay a durable return to profitability.
Persistent Cash BurnThree consecutive years of negative operating cash flow indicate that reported operations are not funding the business. Continued losses could require external financing, reducing flexibility and potentially diluting existing shareholders unless the revenue rebound converts into cash generation.
Weakening Capital Cushion And No DividendThe lower equity ratio shows that continuing losses are consuming part of the capital cushion, even though leverage remains low. The absence of dividends also provides no shareholder income while the company must retain resources to fund recovery and ongoing operations.
Tsubota Laboratory Incorporated News
4890 FAQ
What was Tsubota Laboratory Incorporated’s price range in the past 12 months?
Tsubota Laboratory Incorporated lowest stock price was ¥210.00 and its highest was ¥478.00 in the past 12 months.
What is Tsubota Laboratory Incorporated’s market cap?
Tsubota Laboratory Incorporated’s market cap is ¥7.19B.
When is Tsubota Laboratory Incorporated’s upcoming earnings report date?
Tsubota Laboratory Incorporated’s upcoming earnings report date is Nov 06, 2026 which is in 73 days.
How were Tsubota Laboratory Incorporated’s earnings last quarter?
Tsubota Laboratory Incorporated released its earnings results on Aug 12, 2026. The company reported -¥5.2 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Tsubota Laboratory Incorporated overvalued?
According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued.
Does Tsubota Laboratory Incorporated pay dividends?
Tsubota Laboratory Incorporated does not currently pay dividends.
What is Tsubota Laboratory Incorporated’s EPS estimate?
Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsubota Laboratory Incorporated have?
Tsubota Laboratory Incorporated has 25,969,738 shares outstanding.
What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?
Tsubota Laboratory Incorporated reported an EPS of -¥5.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.23%.
Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?
Currently, no hedge funds are holding shares in JP:4890
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsubota Laboratory Incorporated
Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and presbyopia.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
COSMOS Pharmaceutical Corporation
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―